These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine. Wong G mBio; 2019 Jul; 10(4):. PubMed ID: 31311887 [TBL] [Abstract][Full Text] [Related]
13. Correlates of vaccine-induced protective immunity against Ebola virus disease. Medaglini D; Santoro F; Siegrist CA Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831 [TBL] [Abstract][Full Text] [Related]
14. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Wu L; Zhang Z; Gao H; Li Y; Hou L; Yao H; Wu S; Liu J; Wang L; Zhai Y; Ou H; Lin M; Wu X; Liu J; Lang G; Xin Q; Wu G; Luo L; Liu P; Shentu J; Wu N; Sheng J; Qiu Y; Chen W; Li L Hum Vaccin Immunother; 2017 Sep; 13(9):2078-2085. PubMed ID: 28708962 [TBL] [Abstract][Full Text] [Related]
15. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231 [TBL] [Abstract][Full Text] [Related]
16. Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins. Koch T; Rottstegge M; Ruibal P; Gomez-Medina S; Nelson EV; Escudero-Pérez B; Pillny M; Ly ML; Koundouno FR; Bore JA; Magassouba N; Dahlke C; Günther S; Carroll MW; Addo MM; Muñoz-Fontela C Viruses; 2020 Aug; 12(9):. PubMed ID: 32825479 [TBL] [Abstract][Full Text] [Related]
17. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915 [No Abstract] [Full Text] [Related]
18. Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. Fries L; Cho I; Krähling V; Fehling SK; Strecker T; Becker S; Hooper JW; Kwilas SA; Agrawal S; Wen J; Lewis M; Fix A; Thomas N; Flyer D; Smith G; Glenn G J Infect Dis; 2020 Jul; 222(4):572-582. PubMed ID: 31603201 [TBL] [Abstract][Full Text] [Related]
19. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083 [TBL] [Abstract][Full Text] [Related]